Loading clinical trials...
Loading clinical trials...
In the pediatric field, especially in newborns, the appearance of pressure ulcers is a very frequent event, with prolonged hospitalization, increased costs and worsening of the newborn's clinical picture National data on the prevalence and incidence of pressure ulcers (LP) are not easily available, especially if referred to pediatric and neonatal settings; However, there are guidelines and recommendations issued by scientific societies based on national data on an adult population. The guidelines produced by NPUAP and EPUAP underline the importance of using a tool to assess the risk of pressure ulcers that includes, among the items, the presence of a device as a favorable factor. However, the scales most used in the pediatric/neonatal field for risk assessment do not include it. These scales are the Braden Q Scale, the Glamorgan Scale and the NSRAS The overall objective of this Single-Centre Observational study is to describe the validity and reliability of the Braden QD Scale (Italian version) in the neonatal population. Population enrolled: Newborns who will be part of the Braden QD Scale validation study will be placed in the standard Neonatal Intensive Care Unit (NICU) setting; they will then be admitted to the OU in a thermocot, cot or neonatal island. All devices are provided with an anti-decubitus mattress certified by the manufacturers; in addition, all newborns are placed under the head with a water or gel mattress to further reduce the risk of pressure injury. * Newborns admitted to the Neonatal Intensive Care Unit (NICU) who are less than 28 days old at the time of admission, * Newborns with a body weight of less than 5 kg, at the time of admission The main questions it aims to answer are: * Is the Braden QD Scale the optimal instrument for detecting the risk of pressure injury, in such a complex context as that of the Neonatal Intensive Care Unit? * Can the Braden QD Scale detect and measure the risk of pressure injuries from devices placed on the Neonate?
Infants who will be part of the Braden QD Scale validation study will be placed in the standard Neonatal Intensive Care Unit (NICU) setting; they will then be admitted to the OU in a thermocot, cot or neonatal island. All devices are provided with an anti-decubitus mattress certified by the manufacturers; in addition, all newborns are placed under the head with a water or gel mattress to further reduce the risk of pressure injury. The fabric used in the incubators and other equipment is standard, supplied by the Fondazione I.R.C.S. Policlinico San Matteo di Pavia and from a single company for both washing and rental. As per the protocol in use within the UOC and in accordance with international literature, the newborns undergo a change of posture or decubitus every 2/3 hours. * In the 30 minutes following the meal, the infants are placed in the anti-reflux position, tilting the table about 30°, in order to facilitate gastric emptying and reduce the risk of reflux or regurgitation * The first measurement of the scale will be carried out, after enrolment and assessment of the hydration status of the skin according to the rating scale in use in the Foundation, following morning hygiene care and the second assessment by the end of the daily shift (maximum within 6 hours) on the day of enrolment, by a different operator, as per the procedure described in the original study. * Subsequent surveys will follow the scheme proposed by Curley et al. (2018), but instead of being organised according to days of the week, they will be divided as follows: * first survey on the day of enrolment, * second survey approximately 48 hours later, * third survey 48 hours after the second survey. * In the second week of enrolment, starting on the same day as the first survey, the pattern described above is repeated. * In the following two weeks, the survey will be carried out on the day of the week coinciding with the day of enrolment. All first surveys will be carried out after the hygienic care of the newborn, in the morning shift. During the first survey, operator A will carry out an assessment during hygienic care, an ideal time to observe the infant's skin integrity; operator B will carry out the assessment 6 hours after operator A who, in turn, will repeat it again within 12 hours. With this scheme, the maximum duration of measurements will be 28 days or until discharge, whichever comes first. The appearance of pressure lesions will be grounds for discontinuing the measurements. A construct correlation will be performed between the Braden QD Italian version scale and the Neonatal Skin Risk Assessment Scale (NSRAS) (Lund, C.H. \& Osborne, J.W. (2004; Dolack et al., 2013) original version in the first assessment of the first 100 infants. The nurses involved will be previously trained in filling in the scale for a period of approximately 15 days, during which a number of clinical cases will be developed to be assessed and analysed in teams, with the aim of improving knowledge of the scale and making its filling in correct and uniform. The professionals involved will also be shown in advance the author's video tutorial in which she explains, through a detailed description of the items and practical cases, how to fill in the scale, eliminating any further doubts about its compilation. The video tutorial will be translated into Italian and a presentation will be created in order to train the entire nursing team. The professionals The aim of this observational study is to validate the Braden QD Scale (Linguistic-Cultural and Construct Validation) to assess the risk of pressure injuries in the neonatal population.
Age
0 - 0 years
Sex
ALL
Healthy Volunteers
No
Fondazione IRCCS Policlinico San Matteo di Pavia
Pavia, Pavia, Italy
Start Date
July 1, 2020
Primary Completion Date
December 19, 2027
Completion Date
April 19, 2028
Last Updated
February 20, 2026
600
ESTIMATED participants
Lead Sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions